Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Pharmaceuticals (Nasdaq: CRNX) will report Q1 2026 financial results on Thursday, May 7, 2026 after market close and host a conference call at 4:30 p.m. ET.

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) will report Q1 2026 financial results on Thursday, May 7, 2026 after market close and host a conference call at 4:30 p.m. ET.

Dial-in numbers and Meeting ID are provided for domestic and international participants, and a live webcast will be available and archived on the company Investor Relations website.

Argus Apr 9 session

-0.83% close to close Open Argus

Details

News Market Reaction – CRNX

In the Apr 9 session, CRNX declined 0.83%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Crinetics’ Q1 2026 results on May 7, 2026 and the related 4:30...

Analysis

This announcement sets the timing for Crinetics’ Q1 2026 results on May 7, 2026 and the related 4:30 p.m. ET conference call. Investors now have clarity on when updated financials and a business update will be provided. In the past, similar earnings-date notices for CRNX have been followed by only modest share-price moves, with one prior event linked to a 0.85% gain, suggesting this type of news typically acts as logistical rather than fundamental information.

Key Figures

Earnings date: May 7, 2026 Conference call time: 4:30 p.m. ET Domestic dial-in: 1 833-461-5787 +2 more

Earnings date

May 7, 2026

Scheduled Q1 2026 financial results release after market close

Conference call time

4:30 p.m. ET

Start time for Q1 2026 results call and business update

Domestic dial-in

1 833-461-5787

U.S. participant phone number for earnings conference call

International dial-in

1 585-542-9983

International participant phone number for earnings conference call

Meeting ID

173777518

Access ID for the Q1 2026 earnings conference call

Previous Earnings date Reports

1 past event · Latest: Jan 26

Same Type 1 event

1. Jan 26

   Earnings date announcement

   24h Move

   +0.8%

   Set date and time for Q4 and full-year 2025 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, May 7 at 4:30 p.m. ET 

Domestic:	1 833-461-5787
International:	1 585-542-9983
Meeting ID:	173777518

Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section of www.crinetics.com.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Crinetics (CRNX) release its Q1 2026 earnings and hold the conference call?

Crinetics will release Q1 2026 results on Thursday, May 7, 2026 after market close at 4:30 p.m. ET. According to Crinetics, management will discuss results and provide a business update via a live webcast and dial-in conference call.

How can investors join the Crinetics (CRNX) May 7, 2026 conference call and webcast?

Investors can join by phone using the domestic or international dial-in numbers or via a live webcast link on the company website. According to Crinetics, the webcast will be archived in the Investor Relations section for later access.

What are the call dial-in details and Meeting ID for Crinetics (CRNX) May 7, 2026 event?

Domestic dial-in is 1 833-461-5787, international 1 585-542-9983, Meeting ID 173777518 for the May 7, 2026 call. According to Crinetics, participants should connect at least 15 minutes early to ensure a timely connection.

Will the Crinetics (CRNX) May 7, 2026 webcast be available after the live call?

Yes, the webcast will be archived on the company's Investor Relations website after the live event. According to Crinetics, archived access allows investors to replay the presentation and review the business update at their convenience.